TLP
VRTX icon

Trinity Legacy Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Trinity Legacy Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$244K Buy
503
+8
+2% +$3.54K 0.05% 106
2026
Q1 		$220K Buy
495
+15
+3% +$6.99K 0.05% 104
2025
Q4 		$218K Hold
480
– – 0.05% 95
2025
Q3 		$204K Hold
480
– – 0.05% 97
2025
Q2 		$225K Hold
480
– – 0.05% 91
2025
Q1 		$207K Sell
480
-37
-7% -$17.2K 0.05% 91
2024
Q4 		$208K Sell
517
-120
-19% -$55.6K 0.05% 92
2024
Q3 		$309K Sell
637
-12
-2% -$5.76K 0.08% 86
2024
Q2 		$304K Sell
649
-9
-1% -$3.91K 0.09% 82
2024
Q1 		$275K Sell
658
-2
-0.3% -$845 0.08% 86
2023
Q4 		$269K Buy
660
+13
+2% +$4.8K 0.08% 93
2023
Q3 		$225K Buy
+647
New +$226K 0.08% 94
2023
Q2 		– Sell
-654
Closed -$206K – 94
2023
Q1 		$206K Buy
+654
New +$196K 0.08% 85

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Trinity Legacy Partners's VRTX Position: Q2 2026 in Review

Trinity Legacy Partners increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q2 2026, buying an estimated $3.54K and bringing the position to 503 shares worth $244K. The position accounts for 0.05% of the portfolio, ranked #106.

Trinity Legacy Partners first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $309K in Q3 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Trinity Legacy Partners held 503 shares of Vertex Pharmaceuticals worth $244K as of Q2 2026.
  • Trinity Legacy Partners bought 8 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.54K.
  • Vertex Pharmaceuticals made up 0.05% of Trinity Legacy Partners's portfolio in Q2 2026, its #106 holding.
  • Trinity Legacy Partners first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
  • Trinity Legacy Partners's Vertex Pharmaceuticals position peaked at $309K in Q3 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Trinity Legacy Partners's 13F filing for Q2 2026, filed 24 Jul 2026.